During a disease outbreak/pandemic situation such as COVID-19, researchers are in a prime position to identify and develop peptide-based therapies, which could be more rapidly and cost-effectively advanced into a clinical setting. One drawback of natural peptide drugs, however, is their proteolytic instability; peptidomimetics can help to overcome this caveat. In this review, we summarize peptide and peptide-based therapeutics that target one main entry pathway of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which involves the host angiotensin-converting enzyme-2 (ACE2) receptor and viral spike (S) protein interaction. Furthermore, we discuss the advantages of peptidomimetics and other potential targets that have been studied using peptide-based therapeutics for COVID-19.
【저자키워드】 COVID-19, SARS-CoV-2, ACE2, SARS-CoV, peptide, viral entry, Spike protein, peptidomimetics, angiotensin-converting enzyme-2, antagonists, 【초록키워드】 coronavirus, drugs, Protein, target, receptor, disease, Therapies, Interaction, acute respiratory syndrome, help, entry pathway, clinical setting, researcher, Host, identify, develop, peptide-based, overcome, proteolytic, 【제목키워드】 use of peptide,